Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
作者信息
Ragavan Narasimhan, Singh Paras B, Martin Francis L, Baird Andrew D
出版信息
Eur Urol. 2009 Feb;55(2):e43-4. doi: 10.1016/j.eururo.2008.08.061. Epub 2008 Sep 1.
PMID:18771846
Abstract
摘要
相似文献
1
Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
Eur Urol. 2009 Feb;55(2):e43-4. doi: 10.1016/j.eururo.2008.08.061. Epub 2008 Sep 1.
2
Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
Eur Urol. 2009 Feb;55(2):e40-2; author reply e45-6. doi: 10.1016/j.eururo.2008.08.039. Epub 2008 Aug 24.
3
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Eur Urol. 2008 May;53(5):941-9. doi: 10.1016/j.eururo.2007.12.032. Epub 2007 Dec 27.
4
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
J Clin Oncol. 2006 Apr 20;24(12):1868-76. doi: 10.1200/JCO.2005.04.7423.
5
Re: Fritz H. Schröder, Karl-Heinz Kurth, Sophie D. Fossa, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009;55:14-22.
Eur Urol. 2009 May;55(5):e82-3. doi: 10.1016/j.eururo.2008.10.026. Epub 2008 Oct 21.
6
Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.
7
Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99.
Eur Urol. 2005 Dec;48(6):1059-60; author reply 1060-1. doi: 10.1016/j.eururo.2005.08.011. Epub 2005 Oct 25.
8
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21.
9
Duration of androgen suppression in prostate cancer.
N Engl J Med. 2009 Sep 17;361(12):1212; author reply 1212-3. doi: 10.1056/NEJMc091433.
10
Re: Per-Anders Abrahamsson. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010;57:49-59.
Eur Urol. 2010 Jul;58(1):e4; author reply e5-6. doi: 10.1016/j.eururo.2010.03.032. Epub 2010 Mar 26.
Zotero 插件